

Part III – Renal Cell Carcinoma

Select Publications

Brahmer JR et al. **Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.** *N Engl J Med* 2012;366(26):2455-65.

Choueiri TK et al. **Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).** *Proc ASCO 2012*;Abstract 4504.

Chow LQ, Eckhardt SG. **Sunitinib: From rational design to clinical efficacy.** *J Clin Oncol* 2007;25(7):884-96.

Dabydeen DA et al. **Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome.** *Eur J Cancer* 2012;48(10):1519-24.

Escudier BJ et al. **Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) — PISCES study, NCT 01064310.** *Proc ASCO 2012*;Abstract CRA4502.

Eskens F et al. **Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors.** *Proc AACR 2008*;Abstract LB-201.

Grünwald V et al. **An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.** *Eur J Cancer* 2012;48(3):324-32.

Hutson TE et al. **A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).** *Proc ASCO 2012*;Abstract TPS4686.

Lee SH et al. **In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.** *Clin Cancer Res* 2005;11:3633-41.

McDermott DF et al. **Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).** *Proc ASCO 2012*;Abstract 4505.

Motzer RJ et al. **Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.** *Proc ASCO 2012*;Abstract 4501.

Nakamura K et al. **KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.** *Cancer Res* 2006;66(18):9134-42.

Ribas A. **Tumor immunotherapy directed at PD-1.** *N Engl J Med* 2012;366(26):2517-9.

Rini BI et al. **Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.** *Proc ASCO 2012*;Abstract 4503.

Rini BI et al. **Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial.** *Lancet* 2011;378(9807):1931-9.

Topalian SL et al. **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.** *N Engl J Med* 2012;366(26):2443-54.